Does Insurance Cover TMS Therapy? What to Know

Whether TMS is right for you and whether insurance will pay for it are two different questions, and mixing them up costs people real money and real delay. Transcranial magnetic stimulation works by delivering focused magnetic pulses to the prefrontal cortex, a brain region reliably underactive in depression, and there is a well-documented, evidence-based case for it. For years, the assumption among people researching TMS has been that coverage is a coin flip: either your plan happens to cover it or it doesn’t. That is not how it actually works. Coverage exists on paper for nearly every major payer, including Medicare, but it is conditioned on specific, document-heavy criteria that most people never see explained clearly. At SiggyMD, we think care decisions should not hinge on guesswork, which is why the criteria matter more than the plan name on your insurance card.

What This Page Covers

• Whether Medicare and commercial insurance actually cover TMS
• The exact medical necessity criteria payers use to decide
• Why prior authorization is almost never optional
• What happens with TMS coverage for OCD and anxiety specifically
• What to do if a claim gets denied

Yes, Coverage Exists, But It Is Conditional

Medicare Part B and most major commercial insurers, including large national payers, cover TMS for major depressive disorder once specific criteria are met. That “once” is the entire story. A Medicare local coverage determination covering TMS for adults with major depressive disorder sets out the standard that most payers echo in some form: TMS is considered medically reasonable and necessary when a patient has a confirmed diagnosis of severe major depressive disorder, has demonstrated a failure of one or more trials of a pharmacological medication or an intolerance to psychopharmacologic medications, and has an order for the procedure written by a psychiatrist who examined the patient face to face and reviewed the record.

That is a meaningfully different standard than “my doctor thinks TMS would help.” It is a documentation standard, and it rewards patients and clinicians who have kept a clear record of what medications were tried, at what doses, for how long, and what happened.

The Medical Necessity Criteria, in Plain Terms

Breaking down the Medicare standard into its component parts helps explain why some approvals move quickly and others stall.

Requirement	What It Actually Means
Confirmed severe MDD diagnosis	A documented diagnosis meeting current diagnostic criteria for major depressive disorder, not a general mood complaint
Failed or intolerable medication trial	At least one antidepressant tried at an adequate dose for an adequate duration, with clear documentation of the outcome
Face-to-face psychiatric exam	The order for TMS must come from a psychiatrist who personally examined the patient and reviewed the record
Prior authorization (most plans)	Submission of medication history, symptom severity scores, and a letter of medical necessity before treatment starts

Commercial insurers frequently go further than Medicare’s baseline, and it is common for a plan to require documentation of two or more failed antidepressant trials from different drug classes rather than just one. That variation is real, and it is a large part of why coverage can feel unpredictable from one insurer to the next even though the underlying logic, rewarding a documented, exhausted medication history, stays consistent.

Why Prior Authorization Is Rarely Optional

Prior authorization means your treating clinician submits documentation to the insurer before treatment begins, and the insurer reviews it before agreeing to pay. For TMS, that packet typically includes medication history with names, doses, and dates, objective severity scores such as the PHQ-9 or a similar depression rating scale, notes on any psychotherapy tried, and a letter of medical necessity from the prescribing psychiatrist. Some Medicare Advantage plans and most commercial insurers require this step; original Medicare has historically been more likely to review documentation after the fact rather than requiring pre-approval, though this varies by contractor and plan.

Starting treatment before authorization is approved is a real financial risk. If the claim is later denied, the person receiving treatment, not the clinic, is typically responsible for the full cost, which can run into the thousands of dollars for a complete six-week course.

TMS for OCD and Anxiety: A Different Coverage Picture

This is where a lot of confusion starts. TMS received FDA clearance for obsessive-compulsive disorder in 2018, several years after its original 2008 clearance for depression. FDA clearance and insurance coverage are not the same thing. Medicare’s coverage policy for TMS explicitly states that treatment for OCD is not considered medically reasonable and necessary under its current standard, a conclusion its advisory committee reached after reviewing the OCD evidence base and finding it did not yet meet the bar Medicare applies for reasonable and necessary care, even though TMS is legally allowed to be marketed for that indication. Coverage for anxiety follows a similarly narrower path: TMS is FDA-cleared to reduce comorbid anxiety symptoms in people with depression who have not responded to antidepressants, but coverage for anxiety disorders on their own is far less consistent across payers than coverage for depression.

The practical takeaway is that the diagnosis on your claim matters as much as the treatment itself. Confirming your plan’s specific policy for your specific diagnosis, before scheduling anything, saves real time.

If a Claim Gets Denied, It Is Not Necessarily Final

Denials happen, and they are not always the end of the process. A common path to reversal involves the treating clinician submitting additional documentation, such as a more complete medication trial history or updated severity scores, or requesting a peer-to-peer conversation with the insurer’s medical director to walk through the clinical reasoning directly. None of this is guaranteed, but it means a denial is a step in a process, not automatically a dead end.

How Siggy Approaches This

Siggy’s clinical scope today is medication management for anxiety and depression, reviewed and approved by a licensed prescriber. TMS is a separate, procedural treatment delivered in a specialized clinic, and Siggy does not perform it or process TMS insurance claims. Where this matters most for our members is upstream: the exact documentation payers look for when reviewing a TMS request, a clear, dated record of which medications were tried, at what doses, and what happened, is the same record a well-managed medication plan should already be building. Ongoing tracking between visits, rather than sparse notes from a quarterly appointment, is what makes that history usable later if a referral for TMS or another higher level of care becomes appropriate.

What Members Are Saying

JP

J.P., 45

Building a Medication Record Before a TMS Referral

“I didn’t think about insurance criteria until my doctor mentioned TMS as a next step, and then I realized how thin my old medication records actually were. Having a running, dated history made the referral conversation so much easier.”

CL

C.L., 52

Navigating a Prior Authorization Denial

“Our first prior authorization got denied because the paperwork didn’t show how long I’d actually been on the first medication. Getting that timeline straight the second time around made the difference.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

TMS coverage is genuinely available through Medicare and most commercial insurers, but it is earned through documentation, not assumed. A clear, dated history of what medications you have tried and how they went is the single biggest factor in a fast approval. If you are still working through medication options for depression or anxiety, start your anonymous intake with SiggyMD to get a plan reviewed by a licensed prescriber, with the kind of ongoing tracking that builds exactly the record a future TMS referral would need. For the fuller clinical picture of what TMS response rates actually look like, our guide to whether TMS therapy works covers the evidence in detail.

Ready for care that builds a record your next provider can actually use? Get started with SiggyMD today.

Sources

1. Novitas Solutions, Inc. Local Coverage Determination: Transcranial Magnetic Stimulation (TMS) in the Treatment of Adults with Major Depressive Disorder (L34998). Centers for Medicare & Medicaid Services.
2. U.S. Food and Drug Administration. FDA Permits Marketing of Transcranial Magnetic Stimulation for Treatment of Obsessive-Compulsive Disorder. 2018.
3. McClintock SM, Reti IM, Carpenter LL, et al. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. Journal of Clinical Psychiatry. 2018;79(1).